MARKET WIRE NEWS

Kyverna Therapeutics Inc. (NASDAQ : KYTX) Stock

MWN-AI** Summary

MWN-AI** Analysis

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.


Description


Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna¿s pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases.


Quote


Last:$7.68
Change Percent: -2.78%
Open:$7.96
Close:$7.90
High:$7.96
Low:$7.67
Volume:212,187
Last Trade Date Time:06/05/2026 12:44:12 pm

Stock Data


Market Cap:$448,450,247
Float:32,219,865
Insiders Ownership:0.32%
Institutions:24
Short Percent:N/A
Industry:Biotechnology & Life Sciences
Sector:Healthcare
Website:https://www.kyvernatx.com
Country:US
City:Emeryville

Recent News Releases


Subscribe to Our Newsletter

**MWN-AI FAQ is based on asking OpenAI questions about Kyverna Therapeutics Inc. (NASDAQ: KYTX).

Link Market Wire News to Your X Account

Download The Market Wire News App